These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 17059380)

  • 41. Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy.
    Pavie J; Porcher R; Torti C; Medrano J; Castagna A; Valin N; Rusconi S; Ammassari A; Ghosn J; Delaugerre C; Molina JM;
    J Antimicrob Chemother; 2011 Oct; 66(10):2372-8. PubMed ID: 21821627
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phenotypic and genotypic analyses to guide selection of reverse transcriptase inhibitors in second-line HIV therapy following extended virological failure in Uganda.
    Goodall RL; Dunn DT; Pattery T; van Cauwenberge A; Nkurunziza P; Awio P; Ndembi N; Munderi P; Kityo C; Gilks CF; Kaleebu P; Pillay D;
    J Antimicrob Chemother; 2014 Jul; 69(7):1938-44. PubMed ID: 24633208
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Co-formulated abacavir-lamivudine-zidovudine for initial treatment of HIV infection and AIDS.
    Shey MS; Kongnyuy EJ; Alobwede SM; Wiysonge CS
    Cochrane Database Syst Rev; 2013 Mar; 2013(3):CD005481. PubMed ID: 23543540
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppression.
    Gulick RM; Lalama CM; Ribaudo HJ; Shikuma CM; Schackman BR; Schouten J; Squires KE; Koletar SL; Pilcher CD; Reichman RC; Klingman KL; Kuritzkes DR
    AIDS; 2007 Apr; 21(7):813-23. PubMed ID: 17415036
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone.
    Mira JA; López-Cortés LF; Barreiro P; Tural C; Torres-Tortosa M; de Los Santos Gil I; Martín-Rico P; Ríos-Villegas MJ; Hernández-Burruezo JJ; Merino D; López-Ruz MA; Rivero A; Muñoz L; González-Serrano M; Collado A; Macías J; Viciana P; Soriano V; Pineda JA
    J Antimicrob Chemother; 2008 Dec; 62(6):1365-73. PubMed ID: 18854330
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Abacavir: a review of its clinical potential in patients with HIV infection.
    Hervey PS; Perry CM
    Drugs; 2000 Aug; 60(2):447-79. PubMed ID: 10983741
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Virologic response of zidovudine, lamivudine, and tenofovir disoproxil fumarate combination in antiretroviral-naive HIV-1-infected patients.
    Rey D; Krebs M; Partisani M; Hess G; Cheneau C; Priester M; Bernard-Henry C; de Mautort E; Lang JM
    J Acquir Immune Defic Syndr; 2006 Dec; 43(5):530-4. PubMed ID: 17057610
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evidence for a shift to anaerobic metabolism in adipose tissue in efavirenz-containing regimens for HIV with different nucleoside backbones.
    McGee KC; Shahmanesh M; Boothby M; Nightingale P; Gathercole LL; Tripathi G; Harte AL; Shojaee-Moradie F; Umpleby AM; Das S; Al-Daghri NM; McTernan PG; Tomlinson JW
    Antivir Ther; 2012; 17(3):495-507. PubMed ID: 22300946
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cost-effectiveness of nucleoside reverse transcriptase inhibitor pairs in efavirenz-based regimens for treatment-naïve adults with HIV infection in the United States.
    Brogan AJ; Talbird SE; Cohen C
    Value Health; 2011; 14(5):657-64. PubMed ID: 21839403
    [TBL] [Abstract][Full Text] [Related]  

  • 50. TRIZAL study: switching from successful HAART to Trizivir (abacavir-lamivudine-zidovudine combination tablet): 48 weeks efficacy, safety and adherence results.
    Katlama C; Fenske S; Gazzard B; Lazzarin A; Clumeck N; Mallolas J; Lafeuillade A; Mamet JP; Beauvais L;
    HIV Med; 2003 Apr; 4(2):79-86. PubMed ID: 12702127
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Human immunodeficiency virus type 1 reverse transcriptase mutation selection during in vitro exposure to tenofovir alone or combined with abacavir or lamivudine.
    Stone C; Ait-Khaled M; Craig C; Griffin P; Tisdale M
    Antimicrob Agents Chemother; 2004 Apr; 48(4):1413-5. PubMed ID: 15047556
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa.
    DART Virology Group and Trial Team
    AIDS; 2006 Jun; 20(10):1391-9. PubMed ID: 16791013
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effectiveness and safety of simplification from tenofovir-lamivudine (TDF-3TC) to tenofovir-emtricitabine (TDF-FTC) co-formulation (Truvada) in virologically suppressed HIV-infected patients on HAART.
    Palacios R; Hidalgo C; Ríos MJ; Rivero A; Muñoz L; Lozano F; Gutiérrez-Ravé V; Gálvez MC; del Arco A; Santos J
    Eur J Clin Microbiol Infect Dis; 2009 Apr; 28(4):399-402. PubMed ID: 18841401
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Predictors of adherence and virologic outcome in HIV-infected patients treated with abacavir- or indinavir-based triple combination HAART also containing lamivudine/zidovudine.
    Cahn P; Vibhagool A; Schechter M; Soto-Ramirez L; Carosi G; Smaill F; Jordan JC; Pharo CE; Thomas NE; Steel HM
    Curr Med Res Opin; 2004 Jul; 20(7):1115-23. PubMed ID: 15265256
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Abacavir/3TC vs. tenofovir/FTC: interim results from ACTG 5202.
    Albrecht H
    AIDS Clin Care; 2008 Apr; 20(4):28. PubMed ID: 19271262
    [No Abstract]   [Full Text] [Related]  

  • 56. High virological failure rate in HIV patients after switching to a regimen with two nucleoside reverse transcriptase inhibitors plus tenofovir.
    Pérez-Elías MJ; Moreno S; Gutiérrez C; López D; Abraira V; Moreno A; Dronda F; Casado JL; Antela A; Rodríguez MA
    AIDS; 2005 Apr; 19(7):695-8. PubMed ID: 15821395
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy and safety of a quadruple combination Combivir + abacavir + efavirenz regimen in antiretroviral treatment-naive HIV-1-infected adults: La Francilienne.
    de Truchis P; Force G; Welker Y; Mechali D; Pulik M; Chemlal K; Rouveix E; Devidas A; Praindhui D; Mamet JP;
    J Acquir Immune Defic Syndr; 2002 Oct; 31(2):178-82. PubMed ID: 12394796
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Selection of a rare resistance profile in an HIV-1-infected patient exhibiting a failure to an antiretroviral regimen including tenofovir DF.
    Delaugerre C; Roudiere L; Peytavin G; Rouzioux C; Viard JP; Chaix ML
    J Clin Virol; 2005 Mar; 32(3):241-4. PubMed ID: 15722030
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Change to abacavir-lamivudine-tenofovir combination treatment in patients with HIV-1 who had complete virological suppression.
    Hoogewerf M; Regez RM; Schouten WE; Weigel HM; Frissen PH; Brinkman K
    Lancet; 2003 Dec; 362(9400):1979-80. PubMed ID: 14683659
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efavirenz/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen (Atripla®): a review of its use in the management of HIV infection.
    Deeks ED; Perry CM
    Drugs; 2010 Dec; 70(17):2315-38. PubMed ID: 21080746
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.